Cargando…
Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19
In its severe manifestation, coronavirus disease 2019 (COVID-19) compromises oxygenation in a manner that is refractory to maximal conventional support and requires escalation to extracorporeal membrane oxygenation (ECMO). Maintaining ECMO support for extended durations requires a delicately balance...
Autores principales: | Seelhammer, Troy G., Rowse, Phillip, Yalamuri, Suraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315936/ https://www.ncbi.nlm.nih.gov/pubmed/32660924 http://dx.doi.org/10.1053/j.jvca.2020.06.059 |
Ejemplares similares
-
Anticoagulation in COVID-19-positive Patients on Venovenous Extracorporeal Membrane Oxygenation
por: Patel, Mayuri, et al.
Publicado: (2022) -
Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation
por: Ranucci, Marco, et al.
Publicado: (2011) -
Superiority of bivalirudin over heparin anticoagulation therapy for extracorporeal membrane oxygenation? Too early to draw conclusions
por: Gu, Jie, et al.
Publicado: (2023) -
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
por: Valdes, Carlos A., et al.
Publicado: (2023) -
Extracorporeal Membrane Oxygenation Complications in Heparin- and Bivalirudin-Treated Patients
por: Giuliano, Katherine, et al.
Publicado: (2021)